Remon J, Besse B, Aix SP, Callejo A, et al. Overall Survival From the EORTC LCG-163 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol 2024 Feb 7:JCO2301521. doi: 10.1200/JCO.23.01521.
PMID: 38324744